Skip to main content

What the FDA labels say about taking them together

Atazanavir and trastuzumab emtansine

Trastuzumab emtansine's FDA label of April 1, 2026 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name trastuzumab emtansine. The trastuzumab emtansine label: “Concomitant use of strong CYP3A4 inhibitors with KADCYLA should be avoided due to the potential for an increase in DM1 exposure and toxicity.”

Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the trastuzumab emtansine FDA label on DailyMed (effective April 1, 2026).

What does the atazanavir label say about trastuzumab emtansine?

Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name trastuzumab emtansine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed

What does the trastuzumab emtansine label say about atazanavir?

Trastuzumab emtansine label, drug interactions

Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) with KADCYLA should be avoided due to the potential for an increase in DM1 exposure and toxicity.

Source: FDA drug label (KADCYLA), Genentech, Inc., effective April 1, 2026 (SPL set 23f3c1f4-0fc8-4804-a9e3-04cf25dd302e), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

4Atazanavir generic labelers
0Trastuzumab emtansine generic labelers
AtazanavirTrastuzumab emtansine
Labeled forHIVBreast cancer
Boxed warningNoYes
Pharmacy cost (NADAC)$2.23 per capsule 300 mg capsulen/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?